{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:56:07Z","timestamp":1793998567447,"version":"4.8.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017037","name":"Cepheid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017037","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vaginitis is a major cause of healthcare visits in the US, costing over $1.2 billion annually. Point-of-care (POC) nucleic acid amplification tests (NAATs) could improve accuracy of diagnosis and treatment during initial visit for vaginitis compared to send-out NAATs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A secondary analysis of data was collected from test operators at POC testing sites where the Xpert Xpress Multiplex Vaginal Panel test (\u201cMVP test\u201d) was performed. Users completed a survey assessing their experience with the instrument system and the PCR-based MVP test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The MVP test demonstrated consistent performance, measured by positive and negative percent agreement, across all user categories, including both trained and untrained staff. Performance was evaluated based on job function (clinicians, non-clinicians, support staff) and educational level (bachelor\u2019s degree or higher, associate\u2019s degree or some college, high school diploma\/general educational development (GED) with technical certification), with no significant differences in performance (P\u2009&gt;0.082 and P\u2009&gt;0.050, respectively).<\/jats:p>\n                    <jats:p>User feedback from 19 operators showed that 15\/19 (79%) of users found the GeneXpert Xpress Instrument System easy to set up, and 18\/19 (96%) found the test instructions easy to follow. Users described the system as user-friendly with clear instructions and helpful videos. Overall, 19\/19 (100%) agreed that the MVP test was easy to perform.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Availability of accurate POC diagnostics will only be useful if the test can be performed by any potential user. Our study results suggest that the MVP test was acceptable to users and that results were accurate regardless of user qualifications. Thus, this test has the potential to improve the immediate clinical outcome by supporting accurate, same day treatment for causes of vaginitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-11304-8","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T13:38:47Z","timestamp":1754141927000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the user experience for a point of care molecular test for causes of vaginitis"],"prefix":"10.1186","volume":"25","author":[{"given":"Barbara","family":"Van Der Pol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Lillis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving","family":"Nachamkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LaShonda","family":"Crane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Lamar","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Weissfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarthi","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"issue":"5","key":"11304_CR1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/OLQ.0000000000000972","volume":"46","author":"K Peebles","year":"2019","unstructured":"Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High global burden and costs of bacterial vaginosis: A systematic review and Meta-Analysis. Sex Transm Dis. 2019;46(5):304\u201311. https:\/\/doi.org\/10.1097\/OLQ.0000000000000972.","journal-title":"Sex Transm Dis"},{"issue":"4","key":"11304_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1089\/pop.2022.0096","volume":"25","author":"KA Troeger","year":"2022","unstructured":"Troeger KA, Thiel ER, London RS. Optimizing vaginitis diagnosis to reduce health care costs in nonpregnant women utilizing molecular diagnostics. Popul Health Manag. 2022;25(4):449\u201354. https:\/\/doi.org\/10.1089\/pop.2022.0096.","journal-title":"Popul Health Manag"},{"issue":"Suppl 1","key":"11304_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12879-024-09042-4","volume":"24","author":"M Cordioli","year":"2024","unstructured":"Cordioli M, Gios L, Erbogasto A, et al. Clinic-based evaluation of the dual Xpert CT\/NG assay on the GeneXpert system for screening for extragenital chlamydial and gonococcal infections amongst men who have sex with men. BMC Infect Dis. 2024;24(Suppl 1):224. https:\/\/doi.org\/10.1186\/s12879-024-09042-4.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"11304_CR4","doi-asserted-by":"publisher","first-page":"e0174822","DOI":"10.1128\/jcm.01748-22","volume":"61","author":"RA Lillis","year":"2023","unstructured":"Lillis RA, Parker RL, Ackerman R, et al. Clinical evaluation of a new molecular test for the detection of organisms causing vaginitis and vaginosis. J Clin Microbiol. 2023;61(3):e0174822. https:\/\/doi.org\/10.1128\/jcm.01748-22.","journal-title":"J Clin Microbiol"},{"issue":"11","key":"11304_CR5","doi-asserted-by":"publisher","first-page":"e0259593","DOI":"10.1371\/journal.pone.0259593","volume":"16","author":"SS Fuller","year":"2021","unstructured":"Fuller SS, Clarke E, Harding-Esch EM. Molecular chlamydia and gonorrhoea point of care tests implemented into routine practice: systematic review and value proposition development. PLoS ONE. 2021;16(11):e0259593. https:\/\/doi.org\/10.1371\/journal.pone.0259593.","journal-title":"PLoS ONE"},{"issue":"1","key":"11304_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/OLQ.0000000000001083","volume":"47","author":"J Gettinger","year":"2020","unstructured":"Gettinger J, Van Wagoner N, Daniels B, Boutwell A, Van Der Pol B. Patients are willing to wait for rapid sexually transmitted infection results in a university student health clinic. Sex Transm Dis. 2020;47(1):67\u20139. https:\/\/doi.org\/10.1097\/OLQ.0000000000001083.","journal-title":"Sex Transm Dis"},{"issue":"Suppl 1","key":"11304_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12879-024-09057-x","volume":"24","author":"M Shephard","year":"2024","unstructured":"Shephard M, Matthews S, Andrewartha K, et al. Quality control and external quality assessment for the independent clinic-based evaluation of point-of-care testing to detect Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in eight countries. BMC Infect Dis. 2024;24(Suppl 1):203. https:\/\/doi.org\/10.1186\/s12879-024-09057-x.","journal-title":"BMC Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11304-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11304-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11304-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T05:04:46Z","timestamp":1754370286000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11304-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,2]]},"references-count":7,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11304"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11304-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,2]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol for the parent study was reviewed and approved by each site\u2019s institutional review board (Advarra IRB for most sites, University of Pennsylvania IRB, and Louisiana State University Health Sciences Center IRB for their respective sites) and in accordance with the Declaration of Helsinki. All study participants provided informed consent. In addition, minors provided assent and informed consent of a parent or legal guardian prior to participating in the study. The secondary analysis in this article is from the data collected in the parent study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BVDP reports receiving grants to her institution and\/or consulting\/honorarium fees from Abbott Rapid Diagnostics, AmplifiDx, BD Lifesciences, BioM\u00e9rieux, binx health, Cepheid, Hologic, Magic Lifesciences, Preventx, Roche, Sherlock and Visby. RL reports receiving grants to her institution and\/or consulting honorarium fees from Abbott, BD Lifesciences, BioMerieux, Cepheid, Chembio, CovarsaDx, Hologic, OrthoQuidel, Roche, Sherlock, and Visby. IN, LC, JB, LP and AW report receiving support to her\/his institution from Cepheid in support of this project. SY reports receiving support to his institution from Abbott Molecular Diagnostics, BD Lifesciences, Cepheid, Hologic, miDiagnostic, Roche and Sherlock. LP reports receiving support to his institution from Cepheid in support of this project. CH and AR are employed by Cepheid.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"975"}}